Overview

A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI

Status:
NOT_YET_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether "butylphthalide +PCI" combined treatment mode on the basis of traditional drug therapy could reduce myocardial infarct size, improve cardiac function and long-term prognosis of patients with acute myocardial infarction, and verify the drug safety of butylphthalide in the treatment of STEMI within the window period of 12 hours.

Phase:

PHASE3

Details

Lead Sponsor:

Xiangya Hospital of Central South University

Collaborator:

CSPC Pharmaceutical Group Limited

Treatments:

3-n-butylphthalide